|Bid||68.82 x 800|
|Ask||68.86 x 800|
|Day's Range||68.50 - 69.25|
|52 Week Range||33.33 - 73.50|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||49.07|
|Forward Dividend & Yield||0.33 (0.48%)|
|Ex-Dividend Date||Jul 10, 2020|
|1y Target Est||69.82|
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.